July 14, 2003--MOGUL ENTERPRISES, Inc. Receives FDA Clearance to Market Its 4 and 5 French Electrophysiology Diagnostic Catheters

SAN JOSE, CA. — July 14, 2003–MOGUL ENTERPRISES, Inc. (A privately held corporation) today announced that it received US Food and Drug Administration clearance of its 4 & 5 French, up-to-10-electrode electrophysiology diagnostic catheters to market them in the United States of America. The clearance includes steerable and fixed-curve distal shaft versions of the catheter designs.

Jamil Mogul, CEO/Chairperson of MOGUL ENTERPRISES, Inc., stated, "During electrophysiology (EP) study, our innovative 4 & 5 French steerable/fixed-curve EP diagnostic catheters with up to ten electrodes will provide physicians with advantageous features, superior performance and price affordability. The 4 and 5 French catheters add to our exquisite product portfolio, which includes our other FDA-cleared EP diagnostic catheters (3-French steerable/fixed-curve EP catheters with up to 10 electrodes & 6-French steerable/fixed-curve EP catheters with up to 20 electrodes), and contain the following main features:

  • The catheter shaft sizes are 4 French (.053 inch nominal) and 5 French (.066 inch nominal)
  • The distal shaft contains up to ten recording electrodes to encompass a wider intracardiac region
  • The steerable distal shaft has two versions: unidirectional and bi-directional, to more easily access and consistently diagnose different intracardiac regions in a given cardiac chamber
  • The fixed-curve distal shaft has a conventional or custom curve, per the physician’s requirement
  • The distal shaft has various optional lengths, up to 6.0 inches, to conform to heart chamber variations
  • The recording electrodes have various lengths and are offered with various inter-electrode spacing
  • Both the distal and proximal shafts come in soft or stiff material option for better catheter handling
  • The proximal shaft is wire-braided with a proprietary design for better torque transmissibility"

MOGUL ENTERPRISES, Inc. is a highly experienced medical company dedicated to developing innovative and inexpensive medical devices/instrumentation related to cardiovascular Rx/Dx and minimally invasive, general surgeries for fulfilling the needs of budget-constrained hospitals and cost-conscious customers in the USA, Europe, Japan and emerging-market countries.

Jamil Mogul stated, "We believe that affordability of all our EP catheters and the other medical devices and instrumentation that are under development at MOGUL ENTERPRISES, Inc. will help provide an access of modern diagnostic, therapeutic/surgical procedures to millions of patients in small cities/towns in the USA, Canada, Europe, Asia, Africa, Latin (North & South) America, Australia and New Zealand as well."

He also indicated, "Our 4 & 5 French electrophysiology diagnostic catheters will be cost competitive so as to be affordable to the cost-conscious physicians and the budget-constrained hospitals that have a great need of electrophysiology catheters of these sizes with up to ten electrodes in their cardiac catheter laboratories. These catheters will generally be priced 30% below the competition while offering more features and better performance than the competitive catheters in these French sizes."

MOGUL ENTERPRISES, Inc. needs to expand its facility to produce these catheters in a high volume for commercialization. Therefore, it is searching for investment partners to join the company and receive a generous profit share and/or company stocks in exchange for their financial investment.. Simultaneously, it intends to offer an exclusive license on a territory basis to manufacture and/or distribute the catheters.

Contact: Jamil Mogul at 1-408-629-3340 (office) or 1-408-489-2083 (mobile) or e-mail: TheMOGULS@aol.com